Last reviewed · How we verify
AVID200
At a glance
| Generic name | AVID200 |
|---|---|
| Also known as | AVID200 DP, TGFβ receptor ectodomain-IgG Fc fusion protein |
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis (PHASE1)
- A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies (PHASE1)
- MPN-RC 118 AVID200 in Myelofibrosis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AVID200 CI brief — competitive landscape report
- AVID200 updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI